Back to Search
Start Over
CAR-T Cells for the Treatment of Lung Cancer
- Source :
- Life, Vol 12, Iss 4, p 561 (2022)
- Publication Year :
- 2022
- Publisher :
- MDPI AG, 2022.
-
Abstract
- Adoptive cell therapy with genetically modified T lymphocytes that express chimeric antigen receptors (CAR-T) is one of the most promising advanced therapies for the treatment of cancer, with unprecedented outcomes in hematological malignancies. However, the efficacy of CAR-T cells in solid tumors is still very unsatisfactory, because of the strong immunosuppressive tumor microenvironment that hinders immune responses. The development of next-generation personalized CAR-T cells against solid tumors is a clinical necessity. The identification of therapeutic targets for new CAR-T therapies to increase the efficacy, survival, persistence, and safety in solid tumors remains a critical frontier in cancer immunotherapy. Here, we summarize basic, translational, and clinical results of CAR-T cell immunotherapies in lung cancer, from their molecular engineering and mechanistic studies to preclinical and clinical development.
- Subjects :
- CAR-T
adoptive cell therapy
immunotherapy
solid tumors
lung cancer
Science
Subjects
Details
- Language :
- English
- ISSN :
- 20751729
- Volume :
- 12
- Issue :
- 4
- Database :
- Directory of Open Access Journals
- Journal :
- Life
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.7e765f2ef3f4ba0981250f6704e97c3
- Document Type :
- article
- Full Text :
- https://doi.org/10.3390/life12040561